Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel targeted Radio-DARPin against mesothelin (MSLN), in co-development with Orano...Read more
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders Mouse analog of MICVO in a syngeneic model indicated strong activity...Read more
Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated promising anti-tumor activity Combination generated complete responses...Read more
Adding to the Medtronic portfolio of catheter-based lead solutions, the novel OmniaSecure defibrillation lead allows for precise delivery and placement in the right ventricle Heart Rhythm 2025: Late-breaking clinical study results evaluating the OmniaSecure lead for investigational use in the...Read more
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company that it placed a clinical hold on the Company’s Phase 1b study evaluating VYN202 for...Read more
TrenibotE is a first-in-class botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8 hours after administration (earliest assessment time) and shorter duration of effect of 2-3 weeks. If approved, TrenibotE will be the first neurotoxin of its kind...Read more
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Eli Lilly | 24.85 2.89 | $884.58 |
| argenx | 14.25 2.37 | $614.76 |
| Encompass Health | 11.96 11.79 | $113.37 |
| Chemed | 8.96 1.64 | $555.74 |
| Alnylam Pharmaceuticals | 8.95 3.69 | $251.56 |
| Madrigal Pharmaceuticals | 6.86 2.14 | $326.79 |
| Aclarion | 6.76 901.33 | $7.51 |
| McKesson | 6.57 0.95 | $695.00 |
| Intuitive | 6.46 1.27 | $514.59 |
| Stryker | 4.01 1.11 | $365.06 |
| West Pharmaceutical | 3.96 1.88 | $214.55 |
| Ascendis Pharma | 3.70 2.31 | $164.15 |
| Merck | 2.90 3.63 | $82.74 |
| Regeneron Pharmaceuticals | 2.88 0.48 | $602.64 |
| OpGen | 2.87 151.05 | $4.77 |
| Jaguar Health | 2.84 35.24 | $10.90 |
| Addus HomeCare | 2.54 2.59 | $100.58 |
| Semler Scientific | 2.40 6.97 | $36.84 |
| Company | Volume | Last Trade |
|---|---|---|
| Sharps Technology | 74,222,588 | $0.02 |
| Azitra | 42,561,658 | $0.31 |
| China SXT Pharmaceuticals | 37,822,363 | $2.37 |
| Pfizer | 34,342,718 | $22.92 |
| Merck | 27,387,547 | $82.74 |
| Summit Therapeutics | 24,375,957 | $23.17 |
| Acrivon Therapeutics | 15,994,031 | $1.64 |
| Bristol-Myers Squibb | 15,963,969 | $47.90 |
| Gilead Sciences | 14,007,265 | $103.17 |
| Insmed | 13,585,902 | $69.69 |
| Novavax | 13,014,900 | $6.67 |
| Recursion | 12,600,429 | $5.69 |
| Iovance Biotherapeutics | 12,413,776 | $3.51 |
| AbbVie | 10,352,092 | $186.47 |
| PacBio | 9,662,403 | $1.11 |
| Viatris | 9,097,427 | $8.13 |
| UnitedHealth | 9,010,635 | $418.98 |
| Tempus AI | 8,942,642 | $52.87 |
| Centene | 8,408,467 | $57.44 |
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
